What are the preferred single-agent trastuzumab regimens for the treatment of HER2/neu-positive metastatic breast cancer?

Updated: Apr 23, 2020
  • Author: Joseph A Sparano, MD; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print
Answer

Answer

Regimens are as follows:

  • Paclitaxel 175 mg/m 2 IV on day 1 every 3 wk or
  • Paclitaxel 80-90 mg/m 2 IV weekly or
  • Docetaxel 80-100 mg/m 2 IV on day 1 every 3 wk or
  • Docetaxel 35 mg/m 2 IV weekly or
  • Vinorelbine 25 mg/m 2 IV weekly or
  • Capecitabine 1000-1250 mg/m 2 PO BID on days 1-14 every 3 wk

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!